Replies to post #43473 on Biotech Values

[genisi]

NMTI - >I’m not sure which panel you’re referring to<
That would be the FDA's Circulatory System Devices Panel.

P.S. I feel pain just thinking of some device circulates in my system :-)

[loridans]

Dendreon has their day with the FDA on March 29. Provenge, IMO, will be approved, although the whole controversy on immunomodulators makes it challenging.

Calculated risk. If no FDA approval next week--the stock gets clocked back to $2. But if it is approved--$10-$14 is probable.

There is a good overview on prospects for DNDN at thestreet.com that might interest biotech investors here.